SNFGE SNFGE
 
Thématique :
- Foie
Originalité :
Intermédiaire
Solidité :
A confirmer
Doit faire évoluer notre pratique :
Pas encore
 
 
Nom du veilleur :
Professeur Pierre-Emmanuel RAUTOU
Coup de coeur :
 
 
Gastroenterology
  2018/08  
 
  2018 Aug;155(2):307-310.e2.  
  doi: 10.1053/j.gastro.2018.04.014.  
 
  Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.  
 
  Ajmera V, Park CC, Caussy C, Singh S, Hernandez C, Bettencourt R, Hooker J, Sy E, Behling C, Xu R, Middleton MS, Valasek MA, Faulkner C, Rizo E, Richards L, Sirlin CB, Loomba R  
  https://www.ncbi.nlm.nih.gov/pubmed/29660324  
 
 

Abstract

 

Markers are needed to predict progression of nonalcoholic fatty liver disease (NAFLD). The proton density fat fraction, measured by magnetic resonance imaging (MRI-PDFF), provides an accurate, validated marker of hepatic steatosis; however, it is not clear whether the PDFF identifies patients at risk for NAFLD progression. We performed a follow-up study of 95 well-characterized patients with biopsy-proven NAFLD and examined the association between liver fat content and fibrosis progression. MRI-PDFF measurements were made at study entry (baseline). Biopsies were collected from patients at baseline and after a mean time period of 1.75 years. Among patients with no fibrosis at baseline, a higher proportion of patients in the higher liver fat group (MRI-PDFF ≥15.7%) had fibrosis progression (38.1%) than in the lower liver fat group (11.8%) (P = .067). In multivariable-adjusted logistic regression models (adjusted for age, sex, ethnicity, and body mass index), patients in the higher liver fat group had a significantly higher risk of fibrosis progression (multivariable-adjusted odds ratio 6.7; 95% confidence interval 1.01-44.1; P = .049). Our findings associate higher liver fat content, measured by MRI-PDFF, with fibrosis progression.

 

 
Question posée
 
Est-ce que l’abondance de la stéatose par IRM-PDFF est associée à une progression plus rapide de la fibrose chez les malades avec stéatopathie métabolique ?
 
Question posée
 
Dans cette cohorte prospective incluant 95 malades avec stéatopathie métabolique, les malades avec une forte stéatose (>15.7%) avaient plus de progression de la fibrose que les autres, indépendamment de l’âge, du sexe et de l’indice de masse corporelle.
 
Commentaires

Cette étude est préliminaire avec un nombre de malades et un suivi limités.

 
www.snfge.org